Health
Eiger Biopharmaceuticals Files for Chapter 11 Bankruptcy
- Stock plummets after company seeks protection from creditors
- Metabolic disease therapy company will seek to sell assets
This article is for subscribers only.
Eiger Biopharmaceuticals Inc., a company developing therapies for rare metabolic diseases, has filed for bankruptcy.
Publicly traded Eiger listed about $38.8 million in assets and $53.1 million in liabilities in a Chapter 11 petition filed Monday in Dallas. Eiger said it intends to sell all its assets and wind down its operations.